These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 23085896)

  • 1. Comprehensive evaluation of the effects of enalapril on matrix metalloproteinases levels in hypertension.
    Fontana V; Silva PS; Izidoro-Toledo TC; Biagi C; Oliveira EB; Gerlach RF; Tanus-Santos JE
    Cardiovasc Drugs Ther; 2012 Dec; 26(6):511-9. PubMed ID: 23085896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of Angiotensin-converting enzyme inhibitor.
    Sakata Y; Yamamoto K; Mano T; Nishikawa N; Yoshida J; Hori M; Miwa T; Masuyama T
    Circulation; 2004 May; 109(17):2143-9. PubMed ID: 15051632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of a specific endothelin receptor A antagonist and an angiotensin-converting enzyme inhibitor on glomerular mRNA levels for extracellular matrix components, metalloproteinases (MMP) and a tissue inhibitor of MMP in aminonucleoside nephrosis.
    Ebihara I; Nakamura T; Tomino Y; Koide H
    Nephrol Dial Transplant; 1997 May; 12(5):1001-6. PubMed ID: 9175058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Balance between matrix metalloproteinases (MMP) and tissue inhibitors of metalloproteinases (TIMP) in the cervical mucus plug estimated by determination of free non-complexed TIMP.
    Becher N; Hein M; Uldbjerg N; Danielsen CC
    Reprod Biol Endocrinol; 2008 Sep; 6():45. PubMed ID: 18826601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abnormal expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in brain arteriovenous malformations.
    Hashimoto T; Wen G; Lawton MT; Boudreau NJ; Bollen AW; Yang GY; Barbaro NM; Higashida RT; Dowd CF; Halbach VV; Young WL;
    Stroke; 2003 Apr; 34(4):925-31. PubMed ID: 12649522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consistent alterations of circulating matrix metalloproteinases levels in untreated hypertensives and in spontaneously hypertensive rats: a relevant pharmacological target.
    Fontana V; Silva PS; Belo VA; Antonio RC; Ceron CS; Biagi C; Gerlach RF; Tanus-Santos JE
    Basic Clin Pharmacol Toxicol; 2011 Aug; 109(2):130-7. PubMed ID: 21401887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and anti-hypertensive therapy.
    Li-Saw-Hee FL; Edmunds E; Blann AD; Beevers DG; Lip GY
    Int J Cardiol; 2000 Aug; 75(1):43-7. PubMed ID: 11054505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril.
    Edling O; Bao G; Feelisch M; Unger T; Gohlke P
    J Pharmacol Exp Ther; 1995 Nov; 275(2):854-63. PubMed ID: 7473177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human ciliary body after latanoprost.
    Oh DJ; Martin JL; Williams AJ; Peck RE; Pokorny C; Russell P; Birk DE; Rhee DJ
    Invest Ophthalmol Vis Sci; 2006 Mar; 47(3):953-63. PubMed ID: 16505029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of matrix metalloproteinases and their inhibitors in experimental retinal ischemia-reperfusion injury in rats.
    Zhang X; Sakamoto T; Hata Y; Kubota T; Hisatomi T; Murata T; Ishibashi T; Inomata H
    Exp Eye Res; 2002 May; 74(5):577-84. PubMed ID: 12076079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antihypertensive effects exerted by enalapril in mild to moderate hypertension are not associated with changes in the circulating levels of nitric oxide-related markers.
    Silva PS; Fontana V; Palei ACT; Sertório JTC; Biagi C; Tanus-Santos JE
    Eur J Clin Pharmacol; 2011 Apr; 67(4):365-370. PubMed ID: 21305271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of latanoprost on the expression of matrix metalloproteinases and their tissue inhibitors in human trabecular meshwork cells.
    Oh DJ; Martin JL; Williams AJ; Russell P; Birk DE; Rhee DJ
    Invest Ophthalmol Vis Sci; 2006 Sep; 47(9):3887-95. PubMed ID: 16936101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enalaprilat: an intravenous substitute for oral enalapril therapy. Humoral and pharmacokinetic effects.
    Reams GP; Lal SM; Whalen JJ; Bauer JH
    J Clin Hypertens; 1986 Sep; 2(3):245-53. PubMed ID: 3023555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia.
    Lorenzl S; Buerger K; Hampel H; Beal MF
    Int Psychogeriatr; 2008 Feb; 20(1):67-76. PubMed ID: 17697439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein kinase C activation by phorbol ester increases in vitro invasion through regulation of matrix metalloproteinases/tissue inhibitors of metalloproteinases system in D54 human glioblastoma cells.
    Park MJ; Park IC; Hur JH; Rhee CH; Choe TB; Yi DH; Hong SI; Lee SH
    Neurosci Lett; 2000 Sep; 290(3):201-4. PubMed ID: 10963898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulated expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in BALB/c mouse brain challenged with Japanese encephalitis virus.
    Shukla V; Kumar Shakya A; Dhole TN; Misra UK
    Neuroimmunomodulation; 2012; 19(4):241-54. PubMed ID: 22441541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of blood sampling procedure on plasma concentrations of matrix metalloproteinases and their tissue inhibitors.
    Rossignol P; Cambillau M; Bissery A; Mouradian D; Benetos A; Michel JB; Plouin PF; Chatellier G; Jacob MP
    Clin Exp Pharmacol Physiol; 2008 Apr; 35(4):464-9. PubMed ID: 18307742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ACE inhibition reduces activity of the plasminogen/plasmin and MMP systems in the brain of spontaneous hypertensive stroke-prone rats.
    Liebetrau M; Burggraf D; Wunderlich N; Jäger G; Linz W; Hamann GF
    Neurosci Lett; 2005 Mar; 376(3):205-9. PubMed ID: 15721222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and response to angiotensin-converting enzyme inhibition of matrix metalloproteinases 2 and 9 in renal glomerular damage in young transgenic rats with renin-dependent hypertension.
    Bolbrinker J; Markovic S; Wehland M; Melenhorst WB; van Goor H; Kreutz R
    J Pharmacol Exp Ther; 2006 Jan; 316(1):8-16. PubMed ID: 16166267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compared properties of trandolapril, enalapril, and their diacid metabolites.
    Chevillard C; Jouquey S; Bree F; Mathieu MN; Stepniewski JP; Tillement JP; Hamon G; Corvol P
    J Cardiovasc Pharmacol; 1994; 23 Suppl 4():S11-5. PubMed ID: 7527095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.